ADVOCACY
We will transform how pain is understood and treated.
OUR ADVOCACY GOALS & METHODS
We work to:
eliminate impediments to care, including arbitrary limits on medication.
promote education about pain.
promote research funding that reflects how common and costly pain is.
promote access to and payment for a range of pain treatment.
promote care grounded in dignity, science, compassion, and innovation.
We educate about:
the many kinds of pain, and the recognition that chronic pain can be a disease.
the difference between dependence and addiction, and the understanding that people may require and appropriately use medication.
the need for fair and effective pain treatment and research.
the life-limiting and disabling pain consequences of poorly treated pain.
the personal and social costs of our failure to invest in managing pain.
NPAC is a policy-focused advocacy group working for systems level change.
NPAC advocates, in accordance with federal and state laws, to advance research, rights and care for all people in pain.
Unfortunately, we cannot do case work for individual patients nor intervene with their doctors.
OUR ETHICS
Three layers of protection ensure that our work is separated from commercial relationships or interests.
As an organization, we pledge to not accept funds from pharmaceutical companies or others in industry that may create actual or perceived conflicts of interest.
Our team has submitted disclosures, and we have a recusal process.
We receive funding from the Ford Foundation, Boarealis Philanthropy, and individual donors.
RECENT NPAC ADVOCACY
District of Columbia considers relief for medical debt
NPAC submitted the following brief written testimony in support of this effort in Washington, D.C.
FDA’s Draft Guidance for Industry: Development of Non-Opioid Analgesics for Chronic Pain
NPAC filed a formal comment in the Federal Register responding to the FDA’s Draft Guidance for Industry: Development of Non-Opioid Analgesics for Chronic Pain, a guide for research into the development of non-opioid analgesics targeting chronic pain.
Centers for Medicare and Medicaid Services Local Contractor Determination to cease coverage of peripheral nerve blocks for chronic pain in 24 states
NPAC participated in several efforts to fight a move by the Centers for Medicare and Medicaid Services to deny coverage for virtually all peripheral nerve blocks for chronic pain in 24 states.
NPAC drafted and submitted a formal comment, NPAC’s Executive Director co-drafted comments for the US Association for the Study of Pain, and NPAC’s Executive Director participated in developing the comments submitted by the American Academy of Pain Medicine (AAPM) as well as a joint piece for Pain Medicine.
Congressional Appropriations for NIH Research
Jointly with the US Association for the Study of Pain, the Chronic Pain Research Alliance, and the US Pain Foundation, NPAC spearheaded a letter to protect pain research signed by 60 pain professional and patient organizations.
DOE Proposed Change to Accessibility Requirements for New Buildings
NPAC filed a substantive adverse comment to the Department of Energy’s proposal, “Rescinding New Construction Requirements Related to Nondiscrimination in Federally Assisted Programs or Activities,” which threatens to undermine the accessibility to people with disabilities of federal buildings.
FDA Proposed Relabeling of Opioid Analgesics
NPAC sent a comment to the Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, raising concerns regarding the proposed relabeling of Extended-Release/Long-Acting Opioid Analgesics.
FDA Citizen’s Petition to Regulate Narxcare
NPAC submitted a comment to the Food and Drug Administration supporting the Citizen’s Petition on Narxcare, urging the agency to regulate the algorithm given studies showing it results in barriers to care.
DEA Proposed Rule on Telemedicine Prescribing
NPAC submitted extensive comments on the DEA Rule, Special Registrations for Telemedicine, and Limited State Telemedicine.
Comprehensive Evaluation of the Implementation and Uptake of the CDC Clinical Practice Guideline for Prescribing Opioids for Pain
NPAC provided input in response to the CDC’s request for comment on its proposal to evaluate the implementation success of its 2022 Opioid Prescribing Guideline.
National Institutes of Health HEAL Initiative Request for Information
NPAC provided ten recommendations on how the Initiative, which is undergoing strategic planning, can better address the unmet needs of people living with pain.
National Institutes of HEAL ENGAGE Request for Information
NPAC provided input on this new effort by the NIH to to increase public engagement in clinical research and to promote accountability, transparency, and responsiveness to community needs.
HHS/OCR Proposed Updated and Expanded Regulations under Section 504 of the Rehabilitation Act
NPAC submitted comments on discrimination in medical treatment
DEA’s Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances.
NPAC submitted extensive comments opposing DEA’s proposed reduction of the medical supply of opioids for the 8th consecutive year
Advancing Research for Chronic Pain Act
NPAC sent an extensive letter to the Chair and Ranking Member of the Senate HELP Committee supporting this Act
Colorado Adopts Law Protecting Prescription Drugs for Chronic Pain
NPAC is advocating in Colorado to protect prescription drugs for people with pain.
DEA’s Concurrent Proposed Rules on Telemedicine Prescribing of Controlled Medications
NPAC filed extensive comments on DEA proposals to roll back telemedicine prescribing of controlled medications warning of immense patient harm if implemented.
Federation of State Medical Boards
NPAC filed a comment on the Federation of State Medical Board’s draft update to its prescribing guideline.
Health and Human Services Rule
NPAC filed a comment on the Department of Health and Human Services’ proposed rule related to Section 1557 of the Affordable Care Act (ACA), Nondiscrimination in Health Programs and Activities. Our comment focused on discriminatory Clinical Care Algorithms.
Board of Pharmacy Specialties
NPAC filed a letter in support of the Board of Pharmacy Specialties’ effort to establish a pain management pharmacy practice board specialty.
Center for Medicare and Medicaid Services (CMS)
NPAC filed a formal comment on the Center for Medicare and Medicaid Services’ proposal to create a Bundle Payment on Chronic Pain Management. NPAC endorses the idea but highlights several concerns about the bundle’s design and implementation.
CDC 2022 Guideline
NPAC filed its extensive written comment on the CDC’s 2022 proposed prescribing Guideline.
Minnesota Bill
NPAC supported a bill in Minnesota to protect care for people with pain.
US Supreme Court Amicus Brief
NPAC filed an amicus curiae brief in Ruan v. US and Kahn v. US on the proper standard for holding prescribers liable under the Controlled Substances Act. We focused on the “chilling effect” on pain care and risks to patient safety of incorrect standards.
Update:
In June 2022, the Supreme Court Ruled Unanimously (9-0) in Ruan v. US, entirely adopting the argument made by NPAC as Amicus Curiae.
For a full list of NPAC’s Advocacy, visit our Advocacy Archive
ADVOCACY OPPORTUNITIES NPAC IS WATCHING
NPAC is watching a number of activities.
Have a Suggestion? Email info@nationalpain.org.
ADVOCACY HISTORY
Our actions have already influenced important policy change:
• NPAC’s Executive Director presented a symposium and facilitated a SIG breakfast at the annual “Pain Connect” meeting of the American Academy of Pain Management (AAPM), both focused on effectively communicating pain science.
• NPAC began efforts to protect pain research at the National Institutes of Health through the Fiscal Year 2027 Congressional Appropriations Process in collaboration with the US Association for the Study of Pain, the Chronic Pain Research Alliance, and the U.S. Pain Foundation, including:
• submitting bill text proposing $293 million for the pain portfolio of the Helping to End Addiction Long-Term (HEAL) Initiative at the National Institute of Neurological Disorders and Stroke (NINDS), which reflects a 2.7 percent Biomedical Research and Development Price Index adjustment from FY 2026, and accompanying Report language to ensure its effective stewardship.
• submitting Report language on Chronic Pain as a Disease to the Office of the Director that encourages NIH to sustain and strengthen cross-Institute coordination of non-HEAL pain research activities to leverage shared infrastructure and accelerate translation of scientific findings into clinical practice.
• submitting Report language on effective implementation across NIH of the 2025 ENGAGE Report on integrating people with lived experience and the public into all aspects of NIH research from planning through translation.
• NPAC Community Leadership Council member, Quana Madison, was the opening plenary speaker at the US Association for the Study of Pain (USASP)’s Annual Scientific Meeting in Philadelphia.
• NPAC’s Executive Director moderated an afternoon Advocacy Workshop at the USASP’s Annual Scientific Meeting.
• NPAC participated in a meeting of Disability Economic Justice Forum.
• NPAC’s Executive Director moderated and presented symposia at the Canadian Pain Society Annual Meeting in Quebec City; one on Global Advocacy for Pain, and one on Medico-Legal Issues and Pain.
• NPAC’s Executive Director spoke about advocacy for pain at the Southern Pain Society’s Annual Scientific Meeting in New Orleans.
• NPAC’s Executive Director was invited to serve as a committee member of the NIH Helping to End Addiction Long-term (HEAL) Initiative Multi-Disciplinary Working Group (MDWG), from 2026-2030.
• NPAC Board Member Dawn M. Gibson participated in the IASP’s Global Alliance of Partners for Pain Advocacy (GAPPA) meeting as part of her ongoing involvement with the initiative.
• NPAC’s Executive Director participated in the IASP’s Task Force on Animal Testing, an international Delphi process to develop new ethical guidelines for animal testing in pain research.
• NPAC’s Executive Director spearheaded a successful symposium proposal for the World Congress on Pain examining what multidisciplinary pain care means in different countries around the globe.
• NPAC submitted a formal comment in the Federal Register on the FDA’s Draft Guidance for Industry: Development of Non-Opioid Analgesics for Chronic Pain, a guide for research into the development of non-opioid analgesics targeting chronic pain.
• NPAC’s Executive Director, in her capacity as co-chair of the advocacy committee for the US Association for the Study of Pain (USASP), co-drafted USASP’s comment on the FDA’s Draft Guidance submitted in the Federal Register.
• NPAC participated in several efforts to fight a move by the Centers for Medicare and Medicaid Services to deny coverage for virtually all peripheral nerve blocks for chronic pain in 24 states.
• NPAC drafted and submitted formal comments.
• NPAC’s Executive Director co-drafted comments for the USASP, and
• NPAC’s Executive Director participated in developing the comments submitted by the American Academy of Pain Medicine (AAPM) as well as a joint piece for Pain Medicine.
• NPAC’s Executive Director addressed the 2025-2026 class of Mayday Pain and Society Fellows in Washington D.C.
• NPAC’s Executive Director participated in the International Association for the Study of Pain’s (IASP) development of new policy briefs for global pain advocacy.
• NPAC’s Executive Director participated in the IASP’s Task Force on Animal Testing, an international Delphi process to develop new ethical guidelines for animal testing in pain research.
• NPAC testified in support of a new mitigation and transparency effort in Washington D.C. related to. medical debt. Several states and the District of Columbia have or are in the process of addressing medical debt.
• NPAC continued with its advocacy on Capitol Hill to support NIH funding through the 2026 Appropriation Process, hosting meetings with the Appropriations’ Committee Chairperson and the Labor HHS Subcommittee Chair (the committee focused on NIH research).
• NPAC’s Executive Director and NPAC’s Dawn Gibson were interviewed for an in-depth look at the impact of climate change on chronic pain for Inside Climate News.
• NPAC became a founding member of the Disability Economic Policy Research Consortium and attended its first annual meeting co-hosted by the National Academy of Social Insurance the Roosevelt Institute.
• NPAC conducted follow-up meetings on Capitol Hill on preserving the federal pain research budget for FY 2026.
• NPAC’s Executive Director attended the Fall 2025 Council Meeting for the National Institute of Neurological Disorders and Stroke as a Subject Matter Expert.
• NPAC’s Executive Director attended a Board Meeting for the NIH PURPOSE Network, after helping to get the grant funding the project reinstated.
• NPAC’s co-submitted a proposal for the upcoming annual scientific meeting of the US Association for the Study of Pain on Pain and the Courts.
• NPAC co-submitted a proposal on cross-border pain advocacy for the annual meeting of the Canadian Pain Society.
• NPAC spearheaded two proposals on pain advocacy for the International Association for the Study of Pain’s World Congress on Pain.
• NPAC’s Executive Director co-published, Moving beyond pain intensity as the primary outcome measure: the INTEGRATE pain framework and beyond, in the 50th Anniversary Issue of Pain.
• In July, NPAC continued its efforts, described in the May/June accomplishments section, to conduct intensive meetings on Capitol Hill with members of the House and Senate Appropriations Committee, pairing policy leads (Kate Nicholson and Juan Hincapie-Castillo) with researchers and people living with pain, to support health and pain research.
• Reports from both the House and Senate Appropriations Committees endorsed the funding appropriations we requested. Members of both committees will now conference to harmonize both reports and draft a funding bill.
• NPAC presented on its advocacy efforts at the Pain Collaborative Meeting.
• NPAC Testified at the Reagan-Udall Foundation for the Food and Drug Administration’s sixth Online Controlled Substances Summit.
• As part of ongoing collaborative advocacy efforts, NPAC’s Executive Director, Kate Nicholson, became the co-chairperson of the advocacy committee for the US Association for the Study of Pain (USASP).
• NPAC’s Executive Director participated in the monthly meeting of the Global Advocacy Working Group for the International Society for the Study of Pain (IASP).
• NPAC’s Executive Director joined the IASP Presidential Task Force on “Guidelines for the Use of Laboratory Animals in Pain Research”.
• NPAC’s Executive Director co-published the article, A Guide to Engaging with Media to Amplify Health Research, INQUIRY, follow up from a convening and presentation with NIH HEAL Connections on how to engage the media.
• NPAC spearheaded an advocacy strategy to protect pain research, working jointly with the US Association for the Study of Pain, the Chronic Pain Research Alliance, and the US Pain Foundation, including:
• sending a letter to the House and Senate Appropriations Committees signed by 60 professional and patient-focused pain organizations, collectively representing the interests of millions of scientists, healthcare providers, and people living with pain;
• providing a series of advocacy training seminars to teach researchers and people living with pain about the Congressional budget process and how to advocate on Capitol Hill;
• developing talking points and a one-pager itemizing key facts about pain and pain research;
• participating in weekly strategy sessions as Congress moves forward with Appropriations; and
• hosting targeted meetings with Capitol Hill offices
• NPAC filed a substantive adverse comment to the Department of Energy’s proposal, “Rescinding New Construction Requirements Related to Nondiscrimination in Federally Assisted Programs or Activities,” which threatened to undermine the accessibility of federal buildings to people with disabilities.
• NPAC submitted a comment to the Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which is considering relabeling Extended-Release/Long-Acting Opioid Analgesics, articulating our concern that this action may imperil care for people who require these medications.
• NPAC’s Executive Director participated in the two-day May meeting of the National Advisory Neurological Disorders and Stroke Council.
• Several NPAC members participated in the 2025 Annual Scientific Meeting in Toronto, hosted by NPAC advisor and President of the Canadian Pain Society, Hance Clarke.
• NPAC’s Executive Director, Kate Nicholson, and advisors, Sean Mackey and Ethan Nadelmann, gave TED-type keynote talks at the Convocation Hall at the University of Toronto.
• Nicholson also organized and presented a Topical Symposium on Resilience at the CPS meeting with panelists Ethan Nadelmann and Scott Fishman.
• NPAC submitted a formal comment on the Drug Enforcement Agency’s proposed Telemedicine Rule and assembled talking points for harm reduction and health policy organizations to use in their comments.
• NPAC filed a formal comment to the Food and Drug Administration in support of the Citizen’s Petition on Narxcare arguing that the algorithm should be regulated in light of studies showing it creates barriers to care.
• NPAC’s Executive Director, Kate Nicholson, and advisor, Stefan Kertesz, gave interviews for a series by Kerry Dooley Young for Medscape on the dangers of the algorithm.
• NPAC submitted a letter to the Senate Health, Education, Labor, and Pensions (HELP) Committee related to the elimination of the Office of Pain Policy and Planning, the office coordinating pain research, at the National Institutes of Health. The letter resulted in a Congressional Inquiry.
• NPAC’s Executive Director, Kate Nicholson, gave an interview to STAT news about the elimination of the key pain office, the Office of Pain, Policy, and Planning at NIH, and NPAC’s President, Juan Hincapie-Castillo, penned an Op-Ed in The News & Observer on the office’s closure and the likely consequences for people with pain.
• NPAC worked alongside mission-aligned organizations to fight unprecedented cuts in Medicaid.
• NPAC helped to organize an in-depth session on advocacy at the 2025 Annual Scientific Meeting of the US Association for the Study of Pain (USASP) in Chicago, and NPAC’s President, Juan Hincapie-Castillo, spoke as a trainer. (Hincapie-Castillo and Nicholson both serve on the Advocacy Committee for USASP).
• NPAC’s Executive Director participated in the April meeting of the National Advisory Neurological Disorders and Stroke Council.
• NPAC’s Executive Director served as faculty at the 14th Congress of the European Pain Federation in Lyon, France.
• NPAC Submitted an extensive public comment on the Center for Disease Control and Prevention’s proposal to evaluate the impact of its 2022 Prescribing Guidelines.
• NPAC joined the Medicaid Day of Action and continues with advocacy efforts to protect the health safety net.
• NPAC’s Executive Director, Dr. Tamara Baker, and Dr. Monica Mallampalli participated in the NIH Interagency Pain Research Coordinating Committee meetings.
• NPAC’s Executive Director participated in a governing board meeting for the NIH PURPOSE program.
• NPAC’s President and Executive Director planned a 3-hour Advocacy Training Session for scientists and clinicians for the upcoming Scientific Meeting of the US Association for the Study of Pain (USASP).
• NPAC will also offer Symposia at the upcoming scientific meetings of the European Pain Federation (EFIC) (on data harmonization) and the Canadian Pain Society (CPS) (one on pain and human rights, and one on building resilience in pain and substance use disorders).
• NPAC Advisor Mara Baer was interviewed regarding chronic pain for the report on Aging by the Alliance for Health Policy.
• NPAC’s Executive Director spoke with Alyssa Quart for Time magazine about Health Insecurity
• NPAC advisor Dr. Stefan Kertesz was featured in an article about opioid prescribing.
• NPAC’s Executive Director co-authored a Lessons Learned paper for Pain Medicine on the INTEGRATE-Pain global Delphi study to develop core outcome measures for acute, chronic, acute to chronic translation, and episodic pain.
• NPAC’s Executive Director attended the National Advisory Neurological Disorders and Stroke Council fall meeting in Bethesda, Maryland.
• NPAC’s Executive Director attended the fall governing board meeting for the NIH PURPOSE program, which endeavors to build the pain workforce.
• Several members of NPAC were invited to join or chair strategic planning subcommittees to set research priorities for the NIH HEAL Initiative, the money allocated by Congress for pain and use disorders, including Dr. Tamara Baker, Quána Madison, and Kate Nicholson.
• NPAC welcomed former Colorado Senator Joan Ginal to its Board of Directors.
Senator Ginal sponsored SB 144, Prescription Drugs for Chronic Pain, the bill NPAC worked on that became law in 2023.
• NPAC Executive Director spoke on legal and policy issues at the Southern Pain Society Annual Scientific Meeting.
• NPAC’s Executive Director, Kate Nicholson, received the Southern Pain Society’s President’s Distinguished Service Award.
• NPAC’s Executive Director addressed Pain Management at the First Annual Convening of the Pain Collaborative.
• NPAC advisors Dr. Monica Mallampalli and Dr. Tamara Baker and Executive Director Kate Nicholson attended the winter meeting of the Interagency Pain Research Coordinating Committee.
• Several NPAC members spoke during consecutive half-day workshops hosted by the NIH HEAL Pain Research Priorities Subcommittees related to HEAL strategic planning, including Dr. Sean Mackey , Dr. Tamara Baker, Quána Madison, and Kate Nicholson.
• NPAC’s Executive Director met with the National Academies of Sciences, Engineering, and Medicine’s Forum on Aging, Disability, and Independence.
• NPAC’s Executive Director spoke about pain patient abandonment at the CATO Institute.
• NPAC held meetings related to studies, including a national study on pain funded by Cornell Weil, the CSI: Opioids Study on suicide and pain, and a potential PCORI study regarding pain management in older adults.
• NPAC participated in a meeting for the US Association for the Study of Pain Advocacy Committee.
• NPAC responded to the NIH HEAL Initiative’s Request for Information (RFI) related to strategic planning on how the Initiative can better address the unmet needs of people with pain.
• In August,NPAC became one of 48 organizations officially endorsing The Long COVID Research Moonshot Act of 2024, which provides $1 billion in mandatory funding per year for 10 years to the National Institutes of Health (NIH) to support long COVID research, the pursuit of treatments, and the expansion of care. NPAC also supported the House version of the bill.
• NPAC responded to an NIH ENGAGE Request for Information (RFI) on how to to increase public engagement in clinical research and to promote accountability, transparency, and responsiveness to community needs.
• NPAC’s Executive Director organized, moderated, and presented two symposiums at the 50th World Congress on Pain in Amsterdam: Getting Pain on the Policy Agenda: Perspectives from Canada, the U.S., Thailand, and the World Health Organization and Patient Partner Inclusion: The Present and Future of Pain Research.
• NPAC’s Executive Director, Kate Nicholson, and Science & Policy Advisory, Dr. Hance Clarke, delivered a symposium on translating research into effective messaging on pain at the Canadian Pain Society’s Annual Scientific Meeting in Ottawa.
• NPAC’s Executive Director, Kate Nicholson, and Science and Policy Advisor, Dr. Hance Clarke, the President of the Canadian Pain Society, met with the Honourable Minister Ya'ara Saks following the National Congress on Pain in Ottawa on advancing the agenda on pain in Canada.
• NPAC’s Executive Director, Kate Nicholson participated in a Board meeting for the NIH PURPOSE network, which is charged with building the pain workforce.
• At the second annual PURPOSE meeting, NPAC’s Executive Director, Kate Nicholson participated in a panel discussion about the future of pain research, presented awards to emerging researchers, and delivered a talk on how to present research to policymakers and the media.
• NPAC’s Executive Director, Kate Nicholson participated in the National Advisory Neurological Orders and Stroke Council Meeting in Bethesda, Maryland.
• In May, the Department of Health and Human Services issued the final implementing regulation for Section 504 of the Rehabilitation Act of 1973, which covers nondiscrimination in healthcare in federal programs and federal contractors and is the first update to the regulation in forty years. The updated regulation contains an expanded section on medical care that NPAC commented on during the rulemaking process.
• NPAC Board Members Dawn M. Gibson and Ola Ojewumi attended the Borealis Philanthropy convening in Chicago.
• NPAC Community Leadership Council members Charis Hill and Sonya Huber presented at the 2024 NIH Pain Consortium Meeting about their lived experience of pain.
• NPAC’s Executive Director, Kate Nicholson taped two presentations for a side event hosted by the International Association for the Study of Pain at the World Health Assembly in Geneva. The event was in support of a pending global resolution on pain treatment.
• NPAC’s Executive Director, Kate Nicholson, and Board President, Juan Hincapie-Castillo, presented at the annual scientific meeting of the U.S. Association for the Study of Pain, delivering the symposium, Getting Pain on the Policy Agenda: Why Advocacy Matters and How to Do It.
• NPAC’s Executive Director addressed the Canadian Pain Society’s Annual Scientific Meeting in Ottawa.
• NPAC Community Leadership Council Member Quána Madison represented NPAC as a Lived Experience Expert at a National Institutes of Health Workshop.
• NPAC’s Executive Director Kate Nicholson spoke at the Institute of Honor’s Symposium at Washington and Lee University on Addiction and Alienation in America: Corporate Responsibility and the Opioid Crisis, presenting the perspective of pain and medical ethics.
• NPAC’s Executive Director spoke as part of a web series on Navigating Careers in Research for the NIH PURPOSE project on a joint US-EU project to establish core outcome measures (COS) for research for acute pain, chronic pain, episodic pain, and acute to chronic pain translation.
• NPAC’s Executive Director participated as a panelist in the HEAL Connections Sharing Session, Communicating for Impact: Getting Your Research in the Media, a skills-building webinar designed to help train researchers to translate their work to the media.
• NPAC's Executive Director and Board Secretary, Dawn M. Gibson, kicked off the meeting of a new collective called the Pain Collaborative to Advance Equitable Value-Based Solutions.
• NPAC’s Executive Director joined Edward Freeman as a guest on his Stakeholder Podcast. Freeman is an American philosopher and professor of business administration at the Darden School of the University of Virginia known for his work on stakeholder theory and business ethics.
• NPAC successfully testified to support the removal of the Opioid Dosage Threshold for Chronic Noncancer Pain from 2026 Quality Standards for the MEDICAID/CHIP program due to the risk of patient harm. The MEDICAID/CHIP advisory committee voted to remove this provision.
• NPAC partnered with other disability rights organizations to oppose the Census Bureau's proposal to change questions about disability in the 2025 census. The new questions were likely to reduce current estimates of people living with disabilities in the US in ways that could undermine everything from funding to services. The Census Bureau agreed to retain the current questions for 2025.
• NPAC’s Executive Director spoke at the 5th Annual NIH HEAL Initiative Scientific Meeting on the importance of translating and disseminating science to people living with pain and their families.
• NPAC’s Executive Director participated in her first two-day meeting as a subject matter expert for the National Advisory Neurological Disorders and Stroke Council (Council).
• NPAC worked with lawyers at the Legal Action Center on how to evaluate legal claims related to healthcare abandonment and termination of medication.
• NPAC collaborated with Spondylitis Association to deliver a symposium that included talks by Dr. Samina Ali, Dr. Tamara Baker, Dr. Monica Mallampalli, and Kate Nicholson.
• NPAC’s Executive Director met with policymakers on Capitol Hill regarding recent federal legislation related to pain
• As part of ongoing implementation efforts for S.B. 144, a Colorado law protecting people with pain who require opioids, NPAC’s ED published The Last Word in Colorado Medicine, the magazine of the Colorado Medical Society.
• NPAC submitted a formal comment in response to the Department of Health and Human Services’s proposed rule updating the regulation under Section 504 of the Rehabilitation Act of 1973. The comment addressed discrimination in medical treatment.
• NPAC submitted formal comments on the Drug Enforcement Administration’s proposal to reduce the overall supply of certain controlled medications..
• NPAC drafted talking points that were distributed to the harm reduction/drug policy community on the Drug Enforcement Administration’s proposed rule urging public comment.
• NPAC submitted a letter to the Chairman and Ranking Member of the Senate HELP Committee in Support of the Advancing Research for Chronic Pain Act and advising the committee on pain.
• NPAC’s ED presented at the European Pain Federation’s 2023 Congress on a global initiative to establish core research domains for pain. She spoke about involving people living with pain, whose votes were weighted equally to those of researchers and clinicians.
• NPAC was selected to present at the Drug Enforcment Administration’s listening Session on Telemedicine Prescribing. NPAC’s President provided its testimony.
• NPAC successfully advocated with The Board of Pharmacy Specialties (BPS) to create a new specialty in pain management pharmacy.
• NPAC’s Executive Director, Kate Nicholson, and Science and Policy Advisors, Baker and Mallampalli, participated in the fall meeting of the Interagency Pain Research Coordinating Committee.
• NPAC’s Executive Director joined the governing board of NIH PURPOSE, a new initiative to build the pain workforce and support collaboration among researchers.
• NPAC’s Executive Director spoke in Washington, D.C., to the 2023 Mayday Pain and Society Fellows on strategies for advocacy and policy change.
• NPAC’s Executive Director met with policymakers on Capitol Hill regarding recent federal legislation related to pain.
• NPAC worked with the Colorado Medical Society to Implement S.B.144, the Colorado law we supported, by writing about the law in county and state-level provider newsletters and speaking on medical podcasts.
• NPAC’s Executive Director and President were appointed to the advocacy council of the US Association for the Study of Pain (USASP.)
• NPAC worked on a video story in the New York Times that featured Dawn Gibson on how patients who require opioids face impediments to care.
• As part of its partnership with HEAL Connections, NPAC spoke on a learning session panel regarding storytelling for NIH researchers.
• NPAC spoke on Crisis Jam, a broadcast dedicated to suicide prevention.
• NPAC participated in a podcast mini-series offering four recordings on the overdose crisis: two with a focus on pain and two with a focus on addiction.
• NPAC spoke on pain and mental health on a panel for Pain Canada.
• NPAC did a podcast episode for the Opioid REMS training offering a provider and patient perspective.
• NPAC spoke on Off/Kilter Podcast with Rebecca Vallas of The Century Foundation about advocating people living with pain.
• NPAC spearheaded the passage of a new law in Colorado that protects people who require opioids from discrimination at clinics and pharmacies and also protects their providers.
• NPAC presented patient stories before the World Health Organization about the importance of new codes for the diagnosis and treatment of chronic pain.
• NPAC’s ED was featured in a Newsweek cover story and other press.
• NPAC joined a multi-disciplinary summit at Cornell University about digital technology and pain.
• NPAC testified before the California Medical Society to provide input on updating its prescribing guidelines.
• NPAC’s ED spoke at the Canadian Pain Society on the ethical imperative to “do no harm” in treating people with pain and people with addiction.
• NPAC’s Advisor Samina Ali helped spearhead the world’s first standards for treating pain in children.
• NPAC spoke on the safe disposal of medications at a public workshop hosted by the National Academies of Sciences, Engineering, and Medicine.
• NPAC’s Executive Director participated as faculty at the Rx Illicit Drug Summit one of the first times Pain was featured at the summit.
• NPAC’s Executive Director and advisor, Leo Beletsky, published an opinion piece in the Los Angeles Times criticizing the Drug Enforcement Administration’s proposal to limit telemedicine prescribing of controlled medications. The DEA has temporarily extended such prescribing.
• NPAC began work with the HEAL Connections team on a landscape analysis of laws and policies impacting the care of people with pain.
• NPAC’s Executive Director testified in both the Senate and House on SB 144 in Colorado, a bill designed to protect access to medication for people with pain.
• NPAC filed a comment on the Federation of State Medical Boards’ draft updated prescribing guidelines as part of an ongoing effort to work with the FSMB on its update.
• NPAC filed extensive comments on proposed rules issued by the Drug Enforcement Agency on telemedicine prescribing of controlled medications, warning of immense patient harm if the proposals are implemented.
• NPAC Community Leadership Council member, Quana Madison, and advisor, Dr. Sean Mackey, were featured in an article in Nature about chronic pain management.
• NPAC Community Leadership Council member, Charis Hill, and advisors, Dr. Sean Mackey and Dr. Stefan Kertesz were featured in a San Francisco Chronicle piece on barriers to medication and care.
• NPAC began work on a bill in Colorado to protect people with pain who require controlled medications.
• NPAC met with the U.S. Department of Justice on concerns regarding the use of algorithms in pain management..
• NPAC met with the Washington Department of Health to advise against its adoption of Bamboo’s NarxCare scoring.
• NPAC’s Executive Director helped develop the first Consensus Guidelines on Perioperative Cannabis and Cannabinoids, published in January.
• NPAC advisor Dr. Hance Clarke gave an hour-long interview on the CBC/Canadian public broadcaster on failures in chronic pain treatment in Canada.
• NPAC’s Executive Director keynoted a conference on pain management at UCSF.
Two major initiatives NPAC has worked on for years were issued in November:
• The Centers for Disease Control and Prevention (CDC) issued its 2022 updated prescribing guideline rejecting one-sized limits and embracing flexibility in treating pain.
• The Center for Medicare and Medicaid Services (CMS) expanded coverage for chronic pain, including through telehealth, by creating coding for chronic pain management.
• NPAC Board and Community Leadership Council members spoke at the first annual Pain Canada conference.
• NPAC ED was core faculty at the Annual Scientific Meeting of the Association of Regional Anesthesia and Pain Medicine (ARSA).
• NPAC presented at the International Association for the Study of Pain (IASP)’s World Congress on Pain on Prescribing, Tapering, and the Pendulum Swing.
• NPAC’s Executive Director spoke to the Federation of State Medical Boards’ meeting on updating its guidelines on prescribing and PDMPs.
• NPAC facilitated a meeting with the National Academy of Medicine of people living with pain.
• NPAC sent a letter in support of the Board of Pharmacy Specialties’ effort to establish a pain management pharmacy practice board specialty.
• NPAC filed a formal comment on the Department of Health and Human Services' proposed rule related to Section 1557 of the Affordable Care Act (ACA) on Clinical Care Algorithms.
• NPAC’s Executive Director spoke at the National Harm Reduction Conference on why pain management is a harm reduction issue and co-led a session on writing and placing op-eds.
• NPAC held organizational meetings in support of a state pain bill in Colorado.
• NPAC’s Executive Director spoke on Emergency Medical Minute about opioids for pain and the latest studies on tapering.
• NPAC commented on the Center for Medicare and Medicaid Services' proposal to create a payment code for Chronic Pain Management.
• NPAC applied with allied groups for NIH HEAL Initiative grant to establish a Research Dissemination and Engagement Center (awarded in September, under the name HEAL Connections).
• NPAC’s Executive Director joined the advisory board of a joint NIH-EU effort to establish core research domains for acute pain, acute to chronic translation, episodic pain, and chronic pain.
• NPAC’s Executive Director spoke on the importance of Telehealth hosted by Healthy Women.
• NPAC presented a Symposium at the 2022 Scientific Meeting of the U.S. Association for the Study of Pain.
• NPAC worked with the National Academy of Medicine on a Chronic Pain Journey Map.
• The US Supreme Court unanimously adopted the argument made by NPAC in its amicus curiae brief in Ruan v. US. In a case involving the appropriate legal standard for medical providers under the Controlled Substances Act.
• NPAC held a Congressional briefing and conducted meetings with Senate HELP and House Energy and Commerce Committees and other key members related to updates to the Centers for Disease Control and Prevention’s prescribing guideline.
• NPAC filed an extensive written comment on the Centers for Disease Control and Prevention’s proposed prescribing guideline.
• NPAC developed materials to assist patients in filing comments to Centers for Disease Control and Prevention’s Updated Prescribing Guideline.
• Oral argument took place on March 1 in the U.S. Supreme Court on the two cases (including Ruan v. U.S.) in which NPAC submitted an amicus brief related to interpreting the Controlled Substances Act.
• NPAC’s Executive Director and Advisors were widely quoted in media on both the Centers for Disease Control and Preventions Updated Prescribing Guideline and the Supreme Court of Ruan v. U.S., including in the New York Times, Scientific American, the Guardian, Reason, Medpage, and STATnews, among others.
• NPAC supported a bill in Minnesota to protect care for people with pain that was adopted into law.
• NPAC met with the Center for Medicare and Medicaid Services in Atlanta on issues related to chronic pain.
• NPAC met with the Colorado Health Institute on its representation of statistics on opioids (prescribed vs. illicit).
• NPAC an amicus curiae brief in the US Supreme Court cases, Ruan v. US and Kahn v. US, on the proper standard for holding prescribers liable under the Controlled Substances Act. We focused on the “chilling effect” on pain care and risks to patient safety of incorrect and inconsistent standards.
• NPAC presented at the National Academy of Medicine’s Telehealth & Virtual Care Meeting.
• NPAC hosted meetings on Capitol Hill, including with the Senate HELP and House Energy and Commerce Committees, to address concerns regarding pain care.
• Presented about the organization and its mission at the International Association for the Study of Pain’s GAPPA Uplift Conference.
• Presented a webinar about pain advocacy for Pain BC (British Columbia).
• Responded to the American Psychological Associations call for comments on its proposed guideline for treating chronic pain.